These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 11866668)

  • 21. Fondaparinux sodium: a selective inhibitor of factor Xa.
    Bauer KA
    Am J Health Syst Pharm; 2001 Nov; 58 Suppl 2():S14-7. PubMed ID: 11715834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fondaparinux for post-operative venous thrombosis prophylaxis.
    Garces K
    Issues Emerg Health Technol; 2002 Aug; (37):1-4. PubMed ID: 12195605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery.
    Comp PC
    Pharmacotherapy; 2003 Jun; 23(6):772-87. PubMed ID: 12820819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
    Drouet L
    Bull Acad Natl Med; 2003; 187(1):85-96; discussion 96-7. PubMed ID: 14556456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fondaparinux: basic properties and efficacy and safety in venous thromboembolism prophylaxis.
    Bauer KA
    Am J Orthop (Belle Mead NJ); 2002 Nov; 31(11 Suppl):4-10. PubMed ID: 12463577
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide.
    Zhang Y; Zhang M; Tan L; Pan N; Zhang L
    Prog Mol Biol Transl Sci; 2019; 163():41-53. PubMed ID: 31030756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fondaparinux sodium: a review of its use in the prevention of venous thromboembolism following major orthopaedic surgery.
    Reynolds NA; Perry CM; Scott LJ
    Drugs; 2004; 64(14):1575-96. PubMed ID: 15233593
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
    Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; Segers AE; Cariou R; Leeuwenkamp O; Lensing AW;
    Ann Intern Med; 2004 Jun; 140(11):867-73. PubMed ID: 15172900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fondaparinux sodium.
    Keam SJ; Goa KL
    Drugs; 2002; 62(11):1673-85; discussion 1686-7. PubMed ID: 12109927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biochemistry and clinical pharmacology of new anticoagulant agents.
    Samama MM; Gerotziafas GT; Elalamy I; Horellou MH; Conard J
    Pathophysiol Haemost Thromb; 2002; 32(5-6):218-24. PubMed ID: 13679646
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Short- and long-acting synthetic pentasaccharides.
    Koopman MM; Büller HR
    J Intern Med; 2003 Oct; 254(4):335-42. PubMed ID: 12974872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT; Depasse F; Chakroun T; Van Dreden P; Samama MM; Elalamy I
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
    Fukuda T; Kamisato C; Honda Y; Matsushita T; Kojima T; Furugohri T; Morishima Y; Shibano T
    Thromb Res; 2013 Jun; 131(6):540-6. PubMed ID: 23673387
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of low molecular weight heparins and fondaparinux upon thrombin generation triggered by human pancreatic cancer cells BXPC3.
    Gerotziafas GT; Galea V; Mbemba E; Sassi M; Roman MP; Khaterchi A; van Dreden P; Japcowitz M; Lotz JP; Bernaudin JF; Fareed J; Hatmi M; Elalamy I
    Curr Vasc Pharmacol; 2014; 12(6):893-902. PubMed ID: 22724467
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs.
    O'Shaughnessy DF
    Int J Clin Pract; 2004 Mar; 58(3):277-84. PubMed ID: 15117096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fondaparinux (ARIXTRA) as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins.
    Parody R; Oliver A; Souto JC; Fontcuberta J
    Haematologica; 2003 Nov; 88(11):ECR32. PubMed ID: 14607764
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
    Turpie AG
    Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factor Xa inhibitors for acute coronary syndromes.
    Brito V; Ciapponi A; Kwong J
    Cochrane Database Syst Rev; 2011 Jan; (1):CD007038. PubMed ID: 21249686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
    Haas S
    Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin, low-molecular-weight heparins, and heparin pentasaccharide: basic and clinical differentiation.
    Hoppensteadt D; Walenga JM; Fareed J; Bick RL
    Hematol Oncol Clin North Am; 2003 Feb; 17(1):313-41. PubMed ID: 12627673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.